No evidence for increased growth hormone responses to growth hormone-releasing hormone in patients with diabetic retinopathy

Diabetes ◽  
1987 ◽  
Vol 36 (2) ◽  
pp. 159-162 ◽  
Author(s):  
P. Pietschmann ◽  
G. Schernthaner ◽  
F. Prskavec ◽  
C. Gisinger ◽  
H. Freyler
Diabetes ◽  
1987 ◽  
Vol 36 (2) ◽  
pp. 159-162 ◽  
Author(s):  
P. Pietschmann ◽  
G. Schernthaner ◽  
F. Prskavec ◽  
C. Gisinger ◽  
H. Freyler

Nephron ◽  
1996 ◽  
Vol 74 (3) ◽  
pp. 548-554 ◽  
Author(s):  
Juan J. Díez ◽  
Pedro Iglesias ◽  
Julia Sastre ◽  
Javier Méndez ◽  
Rafael Selgas ◽  
...  

2017 ◽  
Vol 114 (50) ◽  
pp. 13248-13253 ◽  
Author(s):  
Menaka C. Thounaojam ◽  
Folami L. Powell ◽  
Sagar Patel ◽  
Diana R. Gutsaeva ◽  
Amany Tawfik ◽  
...  

The potential therapeutic effects of agonistic analogs of growth hormone-releasing hormone (GHRH) and their mechanism of action were investigated in diabetic retinopathy (DR). Streptozotocin-induced diabetic rats (STZ-rats) were treated with 15 μg/kg GHRH agonist, MR-409, or GHRH antagonist, MIA-602. At the end of treatment, morphological and biochemical analyses assessed the effects of these compounds on retinal neurovascular injury induced by hyperglycemia. The expression levels of GHRH and its receptor (GHRH-R) measured by qPCR and Western blotting were significantly down-regulated in retinas of STZ-rats and in human diabetic retinas (postmortem) compared with their respective controls. Treatment of STZ-rats with the GHRH agonist, MR-409, prevented retinal morphological alteration induced by hyperglycemia, particularly preserving survival of retinal ganglion cells. The reverse, using the GHRH antagonist, MIA-602, resulted in worsening of retinal morphology and a significant alteration of the outer retinal layer. Explaining these results, we have found that MR-409 exerted antioxidant and anti-inflammatory effects in retinas of the treated rats, as shown by up-regulation of NRF-2-dependent gene expression and down-regulation of proinflammatory cytokines and adhesion molecules. MR-409 also significantly down-regulated the expression of vascular endothelial growth factor while increasing that of pigment epithelium-derived factor in diabetic retinas. These effects correlated with decreased vascular permeability. In summary, our findings suggest a neurovascular protective effect of GHRH analogs during the early stage of diabetic retinopathy through their antioxidant and anti-inflammatory properties.


1991 ◽  
Vol 53 (2) ◽  
pp. 185-189 ◽  
Author(s):  
Clara V. Alvarez ◽  
Federico Mallo ◽  
Bartolome Burguera ◽  
Luanda Cacicedo ◽  
Carlos Dieguez ◽  
...  

1985 ◽  
Vol 61 (2) ◽  
pp. 223-228 ◽  
Author(s):  
MARIE C. GELATO ◽  
ROGER S. RITTMASTER ◽  
ORA H. PESCOVITZ ◽  
MANUELA CARUSO NICOLETTI ◽  
WILBERT E. NIXON ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document